The White House is promoting a new "intradermal" injection method for the monkeypox vaccine, which allows one traditional dose to be split into five. By injecting the vaccine just under the top layer of skin rather than into fatty tissue, health officials hope to stretch the limited supply. However, the vaccine manufacturer, Bavarian Nordic, has expressed concerns about the lack of data supporting this delivery method and the potential for increased skin reactions.